CGEM

Cullinan Therapeutics, Inc. Common Stock

11.31

USD

+0.51

+4.72%

Nov 06, 15:59 UTC -5

Closed

After-Market

11.30

-0.01

-0.09%

Cullinan Therapeutics, Inc. Common Stock (CGEM) Earnings

CGEM Earnings Reports

Positive Surprise Ratio

CGEM beat 16 of 23 last estimates.

70%

Next Report

Date of Next Report

Mar 08, 2027

Estimate for Q4 26 (Revenue/ EPS)

$14.03M

-$0.85

Implied change from Q3 26 (Revenue/ EPS)

Implied change from Q4 25 (Revenue/ EPS)

+10.39%

Cullinan Therapeutics, Inc. Common Stock earnings per share and revenue

On Nov 05, 2026, CGEM reported earnings of -- USD per share (EPS) for Q3 26, -- the estimate of -0.86 USD, resulting in a --% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference.

Looking ahead to Q4 26, -- analysts forecast an EPS of -0.85 USD, with revenue projected to reach 14.03 million USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Novavax Inc

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.34

Actual

-$0.19

Surprise

+44.56%

Eton Pharmaceutcials, Inc. Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

$0.31

Actual

$1.06

Surprise

+232.50%

Castle Biosciences, Inc. Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.37

Actual

-$0.13

Surprise

+65.32%

Monte Rosa Therapeutics, Inc. Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.29

Actual

$0.03

Surprise

+110.09%

PUMA BIOTECHNOLOGY INC

Report Date

Nov 05, 2026 For Q3 26

Estimate

$0.09

Actual

$0.15

Surprise

+63.40%

Allogene Therapeutics, Inc. Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.15

Actual

-$0.15

Surprise

+0.33%

Arcturus Therapeutics Holdings Inc. Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.69

Actual

-$0.26

Surprise

+62.44%

Anika Therapeutics Inc

Report Date

Nov 06, 2026 For Q3 26

Estimate

$0.06

Actual

$0.28

Surprise

+373.86%

Moderna, Inc. Common Stock

Report Date

Nov 06, 2026 For Q3 26

Estimate

-$1.27

Actual

$0.38

Surprise

+129.79%

Vera Therapeutics, Inc. Class A Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$1.65

Actual

-$1.30

Surprise

+21.33%

FAQ

What were Cullinan Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2026?

For Q3 2026, Cullinan Therapeutics, Inc. Common Stock reported EPS of --, missing estimates by --, and revenue of --, 0% as expectations.

How did the market react to Cullinan Therapeutics, Inc. Common Stock's Q3 2026 earnings?

The stock price moved -- --, changed from -- before the earnings release to -- the day after.

When is Cullinan Therapeutics, Inc. Common Stock expected to report next?

The next earning report is scheduled for Mar 08, 2027.

What are the forecasts for Cullinan Therapeutics, Inc. Common Stock's next earnings report?

Based on -- analysts, Cullinan Therapeutics, Inc. Common Stock is expected to report EPS of -$0.85 and revenue of $14.03M for Q4 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.